


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/247,406
Sheet	1	of	7	Filing Date	February 10, 1999
				First Named Inventor	Michael Caplan
				Group Art Unit	1643 / 627
				Examiner Name	
				Attorney Docket Number	HS 105

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
<i>thw</i>		ABBAS, et al., <u>Cellular and Molecular Immunology</u> . (W.B. Saunders Co., Philadelphia, 1994).	
		BABAKHIN, et al., "Modified allergen immunotherapy: effect on Immunoglobulin E production," <u>Allergy Proc.</u> 16:195-202 (1995).	
		BARBAS, et al., "Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries," <u>J Mol Biol.</u> 230(3):812-23 (1993).	
		BITTER, <u>Methods in Enzymology</u> , Vol. 153, Chapter 33, pp. 516-544 (Wu and Grossman, eds.), Academic Press:New York 1987.	
		BRISTOL, et al. "Development of a murine mutant Ras CD8 + CTL peptide epitope variant that possesses enhanced MHC Class I binding and immunogenic properties," <u>J Immunol.</u> 160(5):2433-41 (1998).	
		BURNS, et al., "Random mutagenesis of the sheep Na,K-ATPase alpha1 subunit generating the ouabain-resistant mutant L793P," <u>J Biol Chem.</u> 271(27):15879-83 (1996).	
		CHALFIE, et al., "Green fluorescent protein as a marker for gene expression," <u>Science.</u> 263(5148):802-5 (1994).	
		CHANG, "Engineering for protein secretion in gram-positive bacteria," <u>Methods in Enzymology</u> , Vol. 153, Chapter 32, pp. 507-516, (Wu and Grossman, eds.), Academic Press:New York 1987.	
		COLIGAN, et al., <u>Current Protocols in Immunology</u> , volume 1, pp. 3.12.I-14, (John Wiley and Sons, 1994).	
<i>✓</i>		COLLEN, et al., "Recombinant Staphylokinase variants with altered immunoreactivity I: Construction and characterization," <u>Circulation</u> 94:197-206 (1996).	

Examiner's Signature	<i>T. Measly</i>	Date Considered	6/19/00
----------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

				Application Number	09/247,406
				Filing Date	February 10, 1999
				First Named Inventor	Michael Caplan
				Group Art Unit	16437
				Examiner Name	
Sheet	2	of	7	Attorney Docket Number	HS 105

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
TW		COLLEN, et al., "Recombinant Staphylokinase variants with altered immunoreactivity III: Species variability of antibody binding patterns," <i>Circulation</i> 95:455-462 (1997).	
		COLMAN, "Production of proteins in the milk of transgenic livestock: problems, solutions, and successes," <i>Am. J. Clin. Nutr.</i> 63(4): 639S-6455S (1996).	
		COLMAN, "Production of therapeutic proteins in the milk of transgenic livestock," <i>Biochem. Soc. Symp.</i> 63:141-147 (1998).	
		CORMACK, et al., "FACS-optimized mutants of the green fluorescent protein (GFP)," <i>Gene</i> 173(1 Spec No):33-8 (1996).	
		DAVIS, et al., <i>Basic Methods in Molecular Biology</i> (Elsevier, New York, 1986).	
		DAY, "Genetic Modification of Proteins in Food," <i>Critical Reviews in Food Science and Nutrition</i> 36(S):S49-S67 (1996).	
		DEMATTEO, et al., "Immunologic barriers to hepatic adenoviral gene therapy for transplantation," <i>Transplantation</i> . 63(2):315-9 (1997).	
		DUFFAUD, et al., "Expression and secretion of foreign proteins in <i>Escherichia coli</i> ," <i>Methods in Enzymology</i> , Vol. 153, Chapters 31, pp.492-507, (Wu and Grossman, eds.), Academic Press:New York 1987.	
		ENCELL, et al., "Engineering Human DNA alkyltransferases for gene therapy using random sequence mutagenesis," <i>Cancer Res.</i> 58(5):1013-20 (1998).	
✓		ESPANION & NIEMANN, "Methods of production and perspectives for use of transgenic domestic animals," <i>DTW Dtsch Tierarztl Wochenschr.</i> 103(8-9):320-8 (1996).	


Examiner's Signature	T. Weerdy	Date Considered	6/19/99
----------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

Application Number	09/247,406
Filing Date	February 10, 1999
First Named Inventor	Michael Caplan
Group Art Unit	1643 16 7
Examiner Name	
Sheet 3 of 7	Attorney Docket Number HS 105

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
TW		FERREIRA, et al., "Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy," <i>FASEB J.</i> 12(2):231-42 (1998).	
		FUCHS & ASTWOOD, FUCHS, et al., "Ingredients for fat replacement," <i>Food Tech.</i> 51:82-87 (1997).	
		HAKKAART, et al. "Epitope mapping of the house-dust-mite allergen Der p 2 by means of site-directed mutagenesis," <i>Allergy</i> 53:165-172 (1998).	
/		HARLOW & LANE, "Antibodies-A Laboratory Manual" (Cold Spring Harbor, 1988).	
/		HSUING, et al., "Expression of bovine growth hormone derivatives in <i>Escherichia coli</i> and the use of the derivatives to produce natural sequence growth hormone by cathepsin C cleavage," <i>Methods in Enzymology</i> , Vol. 153, Chapter 24, pp. 390-401 (Wu and Grossman, eds.), Academic Press:New York 1987.	
/		HUI, et al., "Directing ribosomes to a single mRNA species: A method to study ribosomal RNA mutations and their effects on translation of a single messenger in <i>Escherichia coli</i> ," <i>Methods in Enzymology</i> , Vol. 153, Chapters 27, pp. 432-452 (Wu and Grossman, eds.), Academic Press:New York 1987.	
/		JENNE, et al., "High resolution mapping of the B cell epitopes of staphylokinase in humans using negative selection of a phage-displayed antigen library," <i>J Immunol.</i> 161(6):3161-8 (1998).	
/		JESPERS, et al., "Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage," <i>J Mol Biol.</i> 269(5):704-18 (1997).	
/		JOHNSTONE & THORPE, <i>Immunochemistry in Practice</i> , Third Edition (Blackwell Scientific Publications, Oxford, 1996)	
↓		KAWASAKI, et al., "Identification of three core regions essential for protein splicing of the yeast Vma1 protozyme. A random mutagenesis study of the entire Vma1-derived endonuclease sequence," <i>J Biol Chem.</i> 272(25):15668-74 (1997).	

Examiner's Signature	T. Wenzel	Date Considered	6/19/99
----------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/247,406
Sheet	4	of	7	Filing Date	February 10, 1999
				First Named Inventor	Michael Caplan
				Group Art Unit	1647
				Examiner Name	
				Attorney Docket Number	HS 105

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
TW		KENNETT, et al., <u>Monoclonal Antibodies</u> (Plenum Press:New York, 1980).	
		KIM, et al., "An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production," <i>J Immunol.</i> 158(9):4137-44 (1997).	
		LANTIN, et al., "Anaphylactoid purpura like vasculitis following fibrinolytic therapy: role of the immune response to streptokinase," <i>Clin Exp Rheumatol.</i> 12(4):429-33 (1994).	
		LIGHT & LERNER, "Random mutagenesis of staphylococcal nuclease and phage display selection," <i>Bioorg Med Chem.</i> 3(7):955-67 (1995).	
		LIN-GOERKE, et al., "PCR-based random mutagenesis using manganese and reduced dNTP concentration," <i>Biotechniques.</i> 23(3):409-12 (1997).	
		LITTLE, et al., "Human antibody libraries in Escherichia coli," <i>J Biotechnol.</i> 41(2-3):187-95 (1995).	
		LORENZO & BLASCO, "PCR-based method for the introduction of mutations in genes cloned and expressed in vaccinia virus," <i>Biotechniques.</i> 24(2):308-13 (1998).	
		MILMAN, "Expression plasmid containing the P _L promoter and cl857 repressor," <i>Methods in Enzymology</i> , Vol. 153, Chapters 30, pp. 482-491, (Wu and Grossman, eds.), Academic Press:New York 1987.	
		NAGAI & THØGERSEN, "Synthesis and sequence-specific proteolysis of hybrid proteins produced in <i>Escherichia coli</i> ," <i>Methods in Enzymology</i> , Vol. 153, Chapters 23 to 34 (Wu and Grossman, eds.), Academic Press:New York 1987.	
		The 1995 Lab Manual Source Book (Cold Spring Harbor Laboratory Press:NY, 1995).	


Examiner's Signature	T. Wessely	Date Considered	6/19/99
----------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to the collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/247,406
Sheet	5	of	7
		Attorney Docket Number	HS 105

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>pw</i>		OKADA, et al. "Engineering of hypoallergenic mutants of the <i>Brassica</i> pollen allergen, Bra r 1, for immunotherapy," <i>FEBS Lett.</i> 434:255-260 (1998).	
		PARENT & DEVREOTES, "Isolation of inactive and G protein-resistant adenylyl cyclase mutants using random mutagenesis," <i>J Biol Chem.</i> 270(39):22693-6 (1995).	
		PARIKH & GUENGERICH, "Random mutagenesis by whole-plasmid PCR amplification," <i>Biotechniques.</i> 24(3):428-31 (1998).	
		PICCINI, et al., "Vaccinia virus as an expression vector," <i>Methods in Enzymology</i> , Vol. 153, Chapter 34, pp. 545-563, (Wu and Grossman, eds.), Academic Press:New York 1987.	
		POULSEN, et al., "Improvement of specific immunotherapy by human IgG and modified allergens," <i>Allergy.</i> 44(4):241-55 (1989).	
		REMAUT, et al., "Expression of heterologous unfused protein in <i>Escherichia coli</i> ," <i>Methods in Enzymology</i> , Vol. 153, Chapter 26, pp. 416-431, (Wu and Grossman, eds.), Academic Press:New York 1987.	
		ROONEY & MOORE, "Antiparallel, intramolecular triplex DNA stimulates homologous recombination in human cells," <i>Proc. Natl. Acad. Sci. USA</i> 92: 2141-2144 (1995).	
		ROSENSCHEIN, et al., "Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction," <i>Isr J Med Sci.</i> 27(10):541-5 (1991).	
		SCHNEIDER & BECK, "New expression vectors for identifying and testing signal structures for initiation and termination of transcription," <i>Methods in Enzymology</i> , Vol. 153, Chapter 28, pp. 452-461, (Wu and Grossman, eds.), Academic Press:New York 1987.	
		SCHONER, et al., "Expression of eukaryotic genes in <i>Escherichia coli</i> with a synthetic two-cistron system," <i>Methods in Enzymology</i> , Vol. 153, Chapter 25 (Wu and Grossman, eds.), Academic Press:New York 1987.	

Examiner's Signature	<i>T. Wenzelby</i>	Date Considered	<i>6/19/00</i>
----------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/247,406
		Filing Date	February 10, 1999
		First Named Inventor	Michael Caplan
		Group Art Unit	1643 1627
		Examiner Name	
Sheet	6	of	7
		Attorney Docket Number	HS 105

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
TCW		SCHUMACHER & MITCHELL, "Inhibition of murine reaginic antibody responses by nasal immunotherapy with modified allergen," <i>Int Arch Allergy Appl Immunol.</i> 62(4):382-8 1980.	
		SEHON, "The immunogenicity of recombinant proteins and of "magic bullets" represents the main obstacle for the effective <i>In Vivo</i> targeting of biologic response modifiers (BRMs)," <i>Targeting of Drugs</i> 4:59-65 (1994).	
		SMITH, et al., "Recombinant allergens for immunotherapy: A Der p 2 variant with reduced IgE reactivity retains T-cell epitopes," <i>J. Allergol Clin. Immunol.</i> 101:423-425 (1998).	
		SMITH, et al., "Site-directed mutagenesis of recombinant Der p 2 decreases <i>in vitro</i> and <i>in vivo</i> reactivity with IgE Ab," <i>Journal of Allergy and Clinical Immunology</i> 97:A187 (1996).	
		SODOYER, et al., "Full-scale 'naive' human antibody repertoires assembled from VH and VL variable regions," <i>Hum Antibodies</i> . 8(1):37-42 (1997).	
		STEINBERGER, et al., "Construction of a combinatorial IgE library from an allergic patient. Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5," <i>J. Biol. Chem.</i> 271:10967-10982 (1996).	
		STEINBERGER, et al., "Allergen-specific IgE production of committed B cells from allergic patients <i>in vitro</i> ," <i>J Allergy Clin Immunol.</i> 96(2):209-18 (1995).	
		STEINBERGER, et al., "Expression in <i>Escherichia coli</i> of human IgE antibody fragments with specificity for major timothy grass pollen allergens using the combinatorial library approach," <i>Int Arch Allergy Immunol.</i> 113(1-3):258-9 (1997).	
		STEWARD & STEENSGAARD, "Antibody Affinity: Thermodynamic Aspects and Biological Significance" (CRC Press, 1983).	
↓		SUNG, et al., "Short homopeptide leader sequences enhanced production of human proinsulin in <i>Escherichia coli</i> ," <i>Methods in Enzymology</i> , Vol. 153, Chapter 23 (Wu and Grossman, eds.), Academic Press:New York 1987.	

Examiner's Signature	T. Wenzel	Date Considered	6/17/01
----------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

		Complete if Known	
		Application Number	09/247,406
		Filing Date	February 10, 1999
		First Named Inventor	Michael Caplan
		Group Art Unit	1643 1627
		Examiner Name	
Sheet	7	of	7
		Attorney Docket Number	HS 105

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
THW		TOMLINSON, et al., "The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops," <i>J Mol Biol.</i> 227(3):776-98 (1992).	
		UMETSU, et al., "Th1 and Th2 CD4+ Cells in the pathogenesis of allergic diseases," <i>Proc Soc Exp Biol Med.</i> 215(1):11-20 (1997).	
I		VALENTA, et al., "The immunoglobulin E-allergen interaction: a target for therapy of type I allergic diseases," <i>Int Arch Allergy Immunol.</i> 116(3):167-76 (1998).	
\		WADHWA, et al., "Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy," <i>Clin Exp Immunol.</i> 104(2):351-8 (1996).	
\		YASHUE, et al., "Hyposensitization to allergic reaction in rDer f 2-sensitized mice by the intranasal administration of a mutant of rDer f 2, C8/119S," <i>Clin. Exp. Immunol.</i> 113:1-9 (1998).	
\		ZACCOLO, et al., "An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues," <i>J Mol Biol.</i> 255(4):589-603 (1996).	
		ZILLIOX, et al., "Henoch-Schoenlein purpura due to streptokinase," <i>J Clin Immunol.</i> 13(6):415-23 (1993).	
✓		ZOLOTUKHIN, et al., "A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells," <i>J Virol.</i> 70(7):4646-54 (1996).	

Examiner's Signature	T. Wherry,	Date Considered	6/19/99
----------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.